Testosterone Enanthate Hispanic / Latino Documented Efficacy Gaps

Why Ethnicity Matters for Testosterone Enanthate Response

Testosterone enanthate is the most commonly prescribed injectable testosterone formulation in the United States, yet prescribing protocols treat all men identically regardless of ancestry. This creates a blind spot. Genetic variation in drug-metabolizing enzymes, differences in body composition and fat distribution, and disparate rates of comorbid metabolic disease all influence how a given dose translates into serum testosterone levels and clinical outcomes.

The Pharmacokinetic Chain

After intramuscular injection, testosterone enanthate undergoes ester hydrolysis to release free testosterone. That testosterone is then metabolized primarily by hepatic CYP3A4, CYP3A5, and to a lesser degree CYP19A1 (aromatase). Phase II conjugation through UGT2B17 and UGT2B15 prepares metabolites for renal clearance 1. Each of these enzymes carries population-frequency polymorphisms that differ between Hispanic/Latino and non-Hispanic white men.

The Metabolic Overlay

Hispanic and Latino men carry disproportionate metabolic burden. CDC data from the National Health and Nutrition Examination Survey (NHANES) show a 16.7% age-adjusted diabetes prevalence in Hispanic adults versus 8.0% in non-Hispanic white adults 2. Insulin resistance directly suppresses hypothalamic-pituitary-gonadal axis signaling and lowers sex hormone-binding globulin (SHBG). A man starting testosterone replacement therapy (TRT) with an insulin-resistant phenotype will partition the drug differently than someone without that metabolic context.

Limited Trial Representation

The landmark Testosterone Trials (TTrials), published in the New England Journal of Medicine in 2016, enrolled 790 men aged 65 and older with low testosterone. Only 15.6% of participants identified as Hispanic 1. That sample size was insufficient to power ethnicity-stratified subgroup analyses for most endpoints, leaving clinicians to extrapolate outcomes from a predominantly non-Hispanic white cohort.

CYP Enzyme Polymorphisms and Testosterone Metabolism

Cytochrome P450 enzymes control the oxidative metabolism of testosterone. Variation in CYP3A4 and CYP3A5 activity directly affects how quickly an injected dose of testosterone enanthate is cleared from circulation, which in turn shapes peak-to-trough fluctuations between injections.

CYP3A4 Variants in Hispanic Populations

The CYP3A41B promoter variant (rs2740574) appears at a frequency of approximately 9-11% in Mexican-American populations, compared to 2-9% in European-descent populations and 53-67% in West African-descent populations, according to PharmGKB annotation data 3. This variant has been associated with altered transcriptional activity, though its clinical effect on testosterone clearance has not been isolated in a controlled pharmacokinetic study. Functional data from prostate tissue suggest CYP3A41B may increase intratumoral testosterone catabolism 4.

CYP3A5 Expression Differences

CYP3A51 (the fully functional allele) is expressed at higher rates in populations of African and admixed Latin American descent than in European-descent populations. Among Mexican Americans, CYP3A51 carrier frequency ranges from 25-40%, compared to 10-20% in non-Hispanic white Americans 3. Active CYP3A5 contributes roughly 50% additional CYP3A-mediated clearance capacity when present. For testosterone enanthate, this means a subset of Hispanic patients may metabolize the drug faster, producing lower trough levels on standard every-two-week dosing schedules.

UGT2B17 Deletion Polymorphism

The UGT2B17 gene encodes the primary enzyme responsible for testosterone glucuronidation. A whole-gene deletion polymorphism (del/del genotype) dramatically reduces urinary testosterone glucuronide excretion. In Hispanic/Latino cohorts, the del/del frequency is estimated at 10-15%, sitting between the 7-10% seen in European-descent populations and the 60-80% seen in East Asian populations 5. Men homozygous for the deletion may retain higher circulating testosterone levels from the same dose, potentially increasing estradiol conversion and hematocrit rise.

SHBG, Insulin Resistance, and Bioavailable Testosterone

The relationship between SHBG and testosterone bioavailability is not academic. It determines how much of a measured total testosterone level is actually reaching androgen receptors. Hispanic and Latino men face a compounded disadvantage: low SHBG from metabolic syndrome produces misleadingly "adequate" total testosterone readings while free testosterone remains subtherapeutic, or conversely, makes a given dose appear less effective on paper when the biologically active fraction is actually higher.

The SHBG Depression Effect

SHBG concentrations correlate inversely with insulin levels. In the Multi-Ethnic Study of Atherosclerosis (MESA), Hispanic men had significantly lower SHBG than non-Hispanic white men after adjustment for BMI (mean difference of approximately 3-5 nmol/L) 6. The NHANES III data confirm this pattern, showing SHBG levels 10-20% lower in Mexican-American men with metabolic syndrome compared to BMI-matched white counterparts 7.

Clinical Implications for Dosing

Low SHBG has two competing effects during TRT. On one hand, a larger fraction of administered testosterone circulates unbound and active. On the other, unbound testosterone is cleared more rapidly by hepatic metabolism. The net result depends on individual enzyme activity, body composition, and injection frequency.

A Hispanic man with metabolic syndrome, low SHBG, and a CYP3A5*1 genotype may experience both faster clearance and wider peak-to-trough swings than a metabolically healthy non-Hispanic white man on the same 200 mg every-two-week protocol. This pharmacokinetic profile favors more frequent, lower-dose injections (e.g., 80-100 mg weekly or 50 mg twice weekly) to maintain stable serum levels.

Aromatase Activity and Estradiol

Adiposity drives CYP19A1 (aromatase) expression. Hispanic men have higher rates of central adiposity at any given BMI compared to non-Hispanic white men 8. Greater visceral fat mass means more aromatase substrate conversion of testosterone to estradiol. Clinicians prescribing testosterone enanthate to Hispanic men with central obesity should monitor estradiol levels at 6-8 weeks and consider dose adjustment before adding an aromatase inhibitor.

What the Testosterone Trials Actually Showed

The TTrials remain the largest placebo-controlled evaluation of testosterone therapy in older men. Seven coordinated trials measured sexual function, physical function, vitality, cognitive function, bone density, anemia correction, and cardiovascular risk.

Enrollment and Subgroup Limitations

Of 790 randomized participants, approximately 123 identified as Hispanic. The trials were powered for overall treatment effects, not ethnic subgroup comparisons 1. No published TTrials analysis reports ethnicity-stratified efficacy or pharmacokinetic data. This represents a significant evidence gap.

Outcomes That Were Measured

Across the full cohort, testosterone gel (not enanthate, though the pharmacodynamic endpoints are formulation-independent for steady-state comparisons) increased sexual activity, sexual desire, and erectile function compared to placebo. Physical function improved modestly. Bone mineral density increased at the spine and hip 1. Whether these benefits were equivalent across racial and ethnic groups is unknown from this dataset.

The TRAVERSE Trial Gap

The TRAVERSE cardiovascular safety trial (N=5,204) published in 2023 provided reassurance that testosterone therapy did not increase major adverse cardiovascular events 9. Hispanic men comprised approximately 17% of enrollment. Cardiovascular event rates were not reported by ethnicity in the primary publication, though the study's statistical design would have been underpowered for ethnic subgroup cardiovascular safety analysis even at that enrollment fraction.

Pharmacogenomic Testing: Current Utility

Pharmacogenomic panels can genotype CYP3A4, CYP3A5, UGT2B17, and other relevant loci. The question is whether this information changes clinical decisions for testosterone enanthate prescribing today.

What PharmGKB Says

The Pharmacogenomics Knowledge Base (PharmGKB) catalogs genetic variants affecting drug response. As of 2026, testosterone has PharmGKB annotations for UGT2B17, CYP3A4, and CYP19A1, but no Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline exists for testosterone dosing 10. The evidence level remains at category 2B-3 for most variant-drug pairs, meaning associations are reported but not yet actionable through formal guidelines.

Practical Use Today

A clinician treating a Hispanic man who shows unexpectedly low trough levels on standard dosing, or conversely, exaggerated hematocrit or estradiol responses, may find pharmacogenomic data explanatory. Testing CYP3A5 and UGT2B17 status costs $200-400 through commercial panels. The clinical action is the same whether or not you test: adjust dose based on measured serum levels at 6-8 weeks. Pharmacogenomic data may, however, help explain why the adjustment was needed and predict future dose-response patterns.

Where the Field Is Heading

The All of Us Research Program, which has enrolled over 413,000 participants with a deliberate emphasis on underrepresented populations (over 50% non-white), is generating paired genomic and clinical phenotype data that will eventually power ancestry-informed testosterone dosing models 11. Until those data mature, clinicians should rely on empiric titration guided by serum levels, symptoms, and safety biomarkers.

Dosing Considerations for Hispanic / Latino Patients

No evidence supports a blanket dose increase or decrease for Hispanic patients starting testosterone enanthate. The evidence does support a more granular monitoring approach.

Starting Dose

The Endocrine Society's 2018 clinical practice guideline recommends testosterone enanthate 75-100 mg intramuscularly weekly or 150-200 mg every two weeks 12. This recommendation does not vary by ethnicity. For Hispanic men with known metabolic syndrome, starting at the lower end (75 mg weekly) and titrating upward based on 6-week trough levels may reduce the risk of supraphysiologic peaks and estradiol excess.

Monitoring Protocol

Standard monitoring includes total testosterone (trough, drawn immediately before the next injection), hematocrit, PSA, and lipid panel at baseline and 6-8 weeks 12. For Hispanic men with low baseline SHBG or known insulin resistance, adding free testosterone (by equilibrium dialysis, not calculated) and estradiol (sensitive LC-MS/MS assay) to the 6-week panel provides actionable data. If estradiol exceeds 40-50 pg/mL with symptoms (fluid retention, gynecomastia), reduce the testosterone dose before considering adjunctive therapy.

Injection Frequency

Twice-weekly subcutaneous injections of 25-50 mg produce more stable serum testosterone concentrations than biweekly 200 mg intramuscular injections. For patients with high CYP3A5 activity (rapid metabolizers) or low SHBG, more frequent dosing narrows the peak-to-trough window and reduces estradiol conversion at peak. A 2019 pharmacokinetic modeling study found that subcutaneous testosterone enanthate 50 mg twice weekly produced coefficient of variation in serum testosterone 42% lower than 200 mg intramuscular every two weeks 13.

Comorbidity Management

Treating insulin resistance concurrently with TRT improves testosterone response. Metformin (1,500-2,000 mg daily, titrated) raises SHBG by approximately 10-20% in insulin-resistant men, which stabilizes testosterone binding kinetics 14. Weight loss of 5-10% body weight can raise total testosterone by 50-100 ng/dL independent of TRT 15. Addressing the metabolic substrate matters as much as adjusting the testosterone dose.

Health Disparities Beyond Pharmacology

Efficacy gaps are not purely pharmacogenomic. Structural factors shape treatment access, adherence, and outcomes in Hispanic/Latino populations receiving testosterone therapy.

Insurance and Access

Hispanic adults are the most likely racial or ethnic group to be uninsured in the United States. As of 2024, 18.0% of Hispanic adults aged 18-64 lacked health insurance, versus 6.6% of non-Hispanic white adults 16. Testosterone enanthate 200 mg/mL (5 mL vial) costs $40-80 at retail, manageable for most patients. But the monitoring labs (testosterone, CBC, metabolic panel) and clinician visits required for safe TRT are cost barriers for uninsured patients.

Language and Health Literacy

Injection technique education, symptom tracking, and understanding of when to seek care for adverse effects (polycythemia symptoms, mood changes) require clear communication. Spanish-language patient education materials for TRT are scarce. A 2022 survey of 14 major U.S. Testosterone clinics found that only 3 offered written injection instructions in Spanish 17.

Provider Bias in Diagnosis

Hispanic men present for hypogonadism evaluation at lower rates than non-Hispanic white men, even after adjusting for insurance status. Contributing factors include lower awareness of testosterone deficiency as a treatable condition and provider assumptions that symptoms such as fatigue or low libido are attributable to work stress or lifestyle 18. Underdiagnosis delays treatment and compresses the window for bone and metabolic benefits that accrue with earlier intervention.

The Evidence Gap and What Comes Next

The current evidence base for testosterone enanthate efficacy in Hispanic/Latino men is characterized by underpowered subgroups, absent pharmacokinetic stratification, and reliance on extrapolation from majority-white trial data.

Three developments may close this gap. First, the All of Us Research Program's emphasis on Latino/Hispanic enrollment (currently 17% of the biobank) will generate pharmacogenomic-clinical outcome pairs at meaningful sample sizes 11. Second, the growing adoption of pharmacogenomic panel testing in primary care may produce real-world data linking CYP3A5 and UGT2B17 genotypes to testosterone dose requirements. Third, the Hispanic Community Health Study / Study of Latinos (HCHS/SOL) ancillary studies are collecting sex hormone data in over 16,000 Hispanic/Latino adults, creating a reference range dataset that could inform population-specific diagnostic thresholds 19.

Until those data arrive, the clinical instruction is direct: treat Hispanic and Latino men with testosterone enanthate using the same evidence-based protocols as any patient, but monitor more frequently in the presence of metabolic syndrome, use measured (not calculated) free testosterone when SHBG is low, and adjust injection frequency before escalating dose when trough levels are subtherapeutic on standard intervals.